The potential value of serum chemerin in patients with breast cancer

Yanfang Song, Xianjin Zhu, Zhen Lin, Li Luo, Dan Wen, Yanfang Song, Xianjin Zhu, Zhen Lin, Li Luo, Dan Wen

Abstract

Breast cancer (BC) is one of the most dangerous malignant diseases in females. However, the reliable serum biomarkers of BC still need to be explored. Chemerin levels have been found to be associated with different types of cancer. This study aimed to evaluate the role of serum chemerin as a biomarker of BC diagnosis, as well as the correlation between serum chemerin levels and clinicopathological features. The serum from 248 BC patients, 30 breast benign tumor patients, and 103 healthy controls were collected and serum chemerin levels were determined with enzyme-linked immunosorbent assay. We found that serum levels of chemerin in BC patients were higher than those in healthy control individuals (p < 0.05). The area under the ROC curve (AUC) for chemerin, CA15-3 and CEA was 0.703, 0.662 and 0.581, respectively, in distinguishing between breast cancer patients from healthy individuals, and the chemerin cutoff value was 100.327 ng/ml with a sensitivity of 56.60% and a specificity of 98.10%. The AUC for chemerin + CA15-3 was 0.822, which was higher than that for chemerin + CEA and CEA + CA15-3. Moreover, serum levels of chemerin were significantly associated with histologic grade, Ki67 expression, and menopausal status. However, no significant association was found between serum levels of chemerin and age, tumor size, metastase, ER status, PR status, and HER-2 status. Overall, our study suggested that the combination of chemerin with CA15-3 achieves relatively better diagnostic performance in the breast cancer. Elevated serum chemerin is associated with Ki67 expression levels and histologic grade.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Serum levels of chemerin, CEA, and CA15-3 in breast cancer patients, breast benign tumors, and healthy controls. The data are presented as median with IQR. **p < 0.01, *p < 0.05.
Figure 2
Figure 2
Receiver operating characteristic curves of chemerin, CEA, and CA15-3 in distinguishing breast cancer patients from healthy controls.

References

    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Li J, Han X. Adipocytokines and breast cancer. Curr. Probl Cancer. 2018;42:208–214. doi: 10.1016/j.currproblcancer.2018.01.004.
    1. Quiroga-Morales LA, et al. Obesity and adipocytokines in breast cancer and benign breast disease. Rev. Med. Inst. Mex. Seguro. Soc. 2018;56:246–254.
    1. Jafari SH, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers. J. Cell Physiol. 2018;233:5200–5213. doi: 10.1002/jcp.26379.
    1. Banin Hirata BK, et al. Molecular markers for breast cancer: prediction on tumor behavior. Dis. Markers. 2014;2014:513158. doi: 10.1155/2014/513158.
    1. Chu DT, et al. The effects of adipocytes on the regulation of breast cancer in the tumor microenvironment: an update. Cells. 2019 doi: 10.3390/cells8080857.
    1. Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The Role of adipokines in breast cancer: current evidence and perspectives. Curr. Obes. Rep. 2019;8:413–433. doi: 10.1007/s13679-019-00364-y.
    1. Banas M, et al. Chemerin is an antimicrobial agent in human epidermis. PLoS ONE. 2013;8:e58709. doi: 10.1371/journal.pone.0058709.
    1. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem. Biophys. Res. Commun. 2010;391:1762–1768. doi: 10.1016/j.bbrc.2009.12.150.
    1. Shin WJ, Zabel BA, Pachynski RK. Mechanisms and functions of chemerin in cancer: potential roles in therapeutic intervention. Front. Immunol. 2018;9:2772. doi: 10.3389/fimmu.2018.02772.
    1. Lin W, Chen YL, Jiang L, Chen JK. Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma. Clin. Lab. 2011;57:879–885.
    1. Pachynski RK, et al. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J. Exp. Med. 2012;209:1427–1435. doi: 10.1084/jem.20112124.
    1. Xu CH, Yang Y, Wang YC, Yan J, Qian LH. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer. Oncotarget. 2017;8:22483–22489. doi: 10.18632/oncotarget.14956.
    1. Liu-Chittenden Y, et al. Serum RARRES2 is a prognostic marker in patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2016;101:3345–3352. doi: 10.1210/jc.2016-1781.
    1. Sieminska L, et al. Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol. Pol. 2018;69:120–127. doi: 10.5603/EP.a2018.0006.
    1. Zhang J, et al. Reduced expression of chemerin is associated with poor clinical outcome in acute myeloid leukemia. Oncotarget. 2017;8:92536–92544. doi: 10.18632/oncotarget.21440.
    1. Yamaguchi Y, Du XY, Zhao L, Morser J, Leung LL. Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J. Biol. Chem. 2011;286:39510–39519. doi: 10.1074/jbc.M111.258921.
    1. Lu Z, et al. The serum biomarker chemerin promotes tumorigenesis and metastasis in oral squamous cell carcinoma. Clin. Sci. (Lond.) 2019;133:681–695. doi: 10.1042/CS20181023.
    1. Imai K, et al. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma. Int. J. Mol. Sci. 2014;15:11294–11306. doi: 10.3390/ijms150711294.
    1. Wang C, et al. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides. 2014;51:131–138. doi: 10.1016/j.peptides.2013.10.009.
    1. Sotiropoulos GP, et al. Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer. Lung Cancer. 2018;125:291–299. doi: 10.1016/j.lungcan.2018.10.010.
    1. El-Sagheer G, Gayyed M, Ahmad A, Abd El-Fattah A, Mohamed M. Expression of chemerin correlates with a poor prognosis in female breast cancer patients. Breast Cancer (Dove Med Press) 2018;10:169–176. doi: 10.2147/BCTT.S178181.
    1. Akin SA, Gedik E, Haznedaroglu E, Dogan AL, Altundag MK. Serum Chemerin Level in Breast Cancer. Int. J. Hematol. Oncol. 2017;27:6.
    1. Treeck O, Buechler C, Ortmann O. Chemerin and Cancer. Int. J. Mol. Sci. 2019 doi: 10.3390/ijms20153750.
    1. Wang N, Wang QJ, Feng YY, Shang W, Cai M. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin. Oral Investig. 2014;18:997–1004. doi: 10.1007/s00784-013-1046-8.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj